These 3 stocks have been beaten down this week, but Cramer says the market’s trash can be your treasure.
Read MorePlus, the ECB cut rates, SmileDirectClub debuted, and Groupon might be about to make an offer for Yelp.
Read MorePlus, Trump bashed the Fed on Twitter again, China just exempted some products from tariffs, and shares of GameStop are tanking.
Read MoreProgress on the trade front has given the market a new set of momentum over the past couple of weeks – enough that the major indices are nearing the all-time highs they set at the end of July. Even so, the unpredictability associated with tariff news and the trade war itself has resulted in a […]
Read MoreAs an investor that prefers to focus on value, my preference is to emphasize stocks that are currently trading at significant discounts to their basic valuation metrics. That usually means that most of my attention is directed on stocks that are also trading at or near to yearly or historical lows. That also means that […]
Read MorePlus, China wants to prevent further escalation in the trade war, Apple is announcing its new iPhones on September 10, and Best Buy reported earnings.
Read MoreThere’s new confusion on the trade war front, big tobacco is reuniting, and the yield curve is worsening.
Read MoreSan Fransisco Fed President Mary Daly says so. Also, Target and Lowe’s deliver earnings beats, more Fed news, and the CBO’s latest budget report.
Read MoreTrade Setup Buy Target $9.34 Sell Target $12.41 Stop Loss $7.44 Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and […]
Read MoreTrade Setup Buy Target $1.52 Sell Target $1.68 Trailing Stop 20% vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III […]
Read MoreTrade Setup Buy Target $11.27 Sell Target $12.83 Trailing Stop 20% Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.
Read MoreTrade Setup Buy Target $0.93 Sell Target 1 $1.22 Trailing Stop 20% Sell Target 2 $1.42 Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could […]
Read MoreTrade Setup Buy Target $2.80 Sell Target 1 $3.34 Trailing Stop 20% Sell Target 2 $3.72 Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized […]
Read MoreIn the last week I’ve been focusing my attention in this space on a few of the biggest, most established names in the pharmaceutical space. It’s an industry that I think is becoming more interesting under current market conditions, as some of these names remain significantly off of multi-year, or even all-time highs even as […]
Read MoreOver the last week, one of the fears that has been driving the market (besides the new constant, which is trade) is the concern over whether the economy is finally at risk to start weakening. For some investors, that fear has led to a “flight to quality,” meaning that they’re starting to look for safe […]
Read More